Literature DB >> 2804911

Identification of epidural neoplasm. Radiography and bone scintigraphy in the symptomatic and asymptomatic spine.

R K Portenoy1, B S Galer, O Salamon, M Freilich, J E Finkel, D Milstein, H T Thaler, M Berger, R B Lipton.   

Abstract

Early identification and treatment of epidural neoplasm, before the development of significant neurologic deficits, provides the best opportunity for a favorable outcome. Among the many patients with symptoms, signs, or scintigraphic or radiographic findings suggesting possible epidural disease, a small proportion will have the lesion. The selection of patients for definitive imaging of the epidural space should be based on a determination of the risk of this complication. In this study, the medical records, plain spinal radiographs, bone scintigraphs and myelograms of 43 patients were analyzed retrospectively to assess the risk of epidural disease associated with specific clinical, radiographic, and scintigraphic findings. Cervical, thoracic, and lumbosacral spinal segments were evaluated independently. Symptomatic segments (SS) (N = 41), defined by focal pain or neurologic dysfunction, were distinguished from asymptomatic segments (AS). At SS, epidural disease was found at 86% and 8% of abnormal and normal spinal radiographs, respectively (P less than 0.001), and at 69% and 0% of abnormal and normal scintigrams, respectively (P less than 0.001), whereas at AS epidural disease occurred in 43% and 3% of abnormal and normal spinal radiographs, respectively (P less than 0.001), and 14% and 7% of abnormal and normal scintigrams, respectively (P = NS). Vertebral collapse was highly predictive of an epidural lesion. Epidural disease occurred in 12% of SS and 0% of AS with an abnormal scintigram and normal radiograph, 86% of SS and 45% of AS with abnormalities on both scintigram and radiograph, and at two AS when both were normal. Decision analysis applied to these data yielded a specific conditional probability of epidural disease for each combination of clinical, scintigraphic, and radiographic findings. These data provide a basis for the selection of patients for additional evaluation of the epidural space before neurologic deficits develop.

Entities:  

Mesh:

Year:  1989        PMID: 2804911     DOI: 10.1002/1097-0142(19891201)64:11<2207::aid-cncr2820641104>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 2.  Causes and treatment of bone pain of malignant origin.

Authors:  B Thürlimann; N D de Stoutz
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

3.  Pain due to epidural tumor in cancer patients. Report of two cases and differential diagnosis.

Authors:  A Caraceni; C Martini; E Zecca; F De Conno; R K Portenoy
Journal:  Ital J Neurol Sci       Date:  1997-10

4.  Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; J.Edson Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 5.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 6.  Common emergencies in cancer medicine: cardiovascular and neurologic syndromes.

Authors:  C R Thomas; E A Edmondson
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

Review 7.  Metastatic epidural spinal cord compression: current concepts and treatment.

Authors:  R Grant; S M Papadopoulos; H M Sandler; H S Greenberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.